United States Food and Drug Administration (USFDA) has classified Aurobindo Pharma’s wholly owned subsidiary -- Eugia Pharma Specialities’ Unit-II situated at Rajasthan as a ‘Official Action Indicated’ (OAI) following an inspection conducted from November 03 to November 14, 2025. At the end of the inspection, a ‘Form 483’ was issued with 09 observations.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
